פרופ' אורי בן-דוד

סגל אקדמי בכיר בגנטיקה מולקולרית של אדם וביוכימיה
גנטיקה מולקולרית של אדם וביוכימיה סגל אקדמי בכיר
ניווט מהיר:
פרופ' אורי בן-דוד
טלפון פנימי: 4729
טלפון נוסף: 4730
Lab Website
Google Scholar
משרד: רפואה, 728

Biography

Prof. Ben-David is a Professor of Cancer Genetics at Tel Aviv University. Prof. Ben-David obtained his Ph.D. from the Hebrew University of Jerusalem, completed his postdoctoral training at the Broad Institute of MIT and Harvard, and established his own research group at Tel Aviv University in October 2019. The Ben-David lab applies genomic and functional approaches to studying chromosomal catastrophes in cancer, focusing on a fundamental trait of cancer, called aneuploidy – a change in the number of chromosomes in cancer cells. Ultimately, his research aspires to expand the understanding of the genetic basis of cancer, and to open new avenues for personalized cancer treatments.

Prof. Ben-David is the recipient of several prestigious grants and awards, including the 2020 AACR ‘Next Generation Star’ Award, the 2020 ‘ERC Starting Grant’, the 2021 Cells ‘Young Investigator Award’, and the 2022 ‘Krill Prize’ by the Wolf Foundation. In 2022 he became a member of the EMBO Young Investigator Program, and in 2024 he became a member of the Israel Young Academy.

Positions

Professor, Department of Human Molecular Genetics & Biochemistry, Faculty of Medicine, Tel-Aviv University

Research

Cancer Aneuploidy

Aneuploidy – the presence of an abnormal number of chromosomes in cancer cells — is characteristic of most tumors, and is rarely observed in normal tissues. It is not fully understood how aneuploidy contributes to tumor formation and progression. Moreover, there are currently no therapeutics that target this hallmark of cancer to  eliminate tumors. We apply a variety of genomic and functional approaches to studying this phenomenon.

Genomic evolution of cancer models

The study of the complex genetics of human cancer depends on reliable cancer model systems. However, these models reflect the biology of actual human tumors only to a certain extent, and they evolve in ways that pose both risks and opportunities for cancer research. We study the genomic stability and evolution of cancer model systems, in order to improve their use in basic research, with an emphasis on aneuploidy research.

Stem cells and cancer

Human stem cells share fundamental characteristics with human cancer cells, and thus make for a unique model system for the study of cancer genetics. We use human stem cells as a tool for aneuploidy research, taking advantage of their inherent chromosomal instability and of their amenability to genome editing.  We also use human stem cells as a tool for the identification of cancer vulnerabilities.

Publications & Grants

PUBLICATIONS

# Corresponding author; * Equally-contributing first-author

 

 

ORIGINAL RESEARCH ARTICLES

 

2025

  1. Laue K. *, Pozzi S.*, Cohen-Sharir Y., Winkler T., Eliezer Y., Israeli Dangoor S., Leikin-Frenkel A.I., Lange K., Zerbib J., Ricci A.A., Sacconi A., Berthelet J., Schäffer A., Barshack I., Medyouf H., Merino D., Blandino G., Bertero L., Satchi-Fainaro R.# and Ben-David U. #. Inactivation of p53 drives breast cancer brain metastasis by altering fatty acid metabolism. Nature Genetics (Accepted in Principle), 2025, https://www.biorxiv.org/content/10.1101/2023.12.20.572490v1 (bioRxiv)

 

  1. Stana R., Ben-David U., Weissman D.B., Ram Y. Evolutionary rescue by aneuploidy in tumors exposed to anti-cancer drugs. Genetics, 2025, doi: 10.1093/genetics/iyaf098, IF=4.4.

 

  1. Rendo V. *, Schubert M. *, Khuu N., Suarez Peredo Rodriguez M.F., Huang K., Swift M., He Y., Zerbib J., Smith R., Raaijmakers J., Chowdhury D., Medema R., Colome-Tatche M., Ben-David U. #, Beroukhim R. #, Foijer F #. A compendium of Amplification-Related Gain of Sensitivity (ARGOS) genes in human cancer. Nature Communications, 2025, 16(1):1077, https://doi.org/10.1038/s41467-025-56301-2, IF=14.7.

 

  1. Zheng S.*, Raz L.*, Zhou L. *, Cohen-Sharir Y., Tian R., Ippolito M.R., Gianotti S., Wardenaar R., Broekhuis M., Rodrigue M.S.P., Wobben S., van den Brink A., Bakker P., Santaguida S., Foijer F.#, and Ben David U.# High CDC20 levels increase sensitivity of cancer cells to MPS1 inhibitors. EMBO Rep, 2025, 26(4):1036-106,1 doi:10.1038/s44319-024-00363-8, IF=8.8.

 

  1. Haj M., Frey Y., Levon A., Maliah A., Ben-Yishay T., Slutsky R., Smoom R., Tzfaty Y., Ben-David U., Levy C., Elkon R., Ziv Y., and Shiloh Y. The cGAS-STING, p38 MAPK and p53 Pathways Link Genome Instability to Accelerated Cellular Senescence in Atm-Deficient Lung Fibroblasts. PNAS, 2025, doi:10.1073/pnas.2419196122 (online ahead of print), IF=9.4.

 

2024

  1. Israeli Dangoor S., Khoury R., Salomon K., Shahar S., Frommer N., Yeini E., Miari A., Leichtmann-Bardoogo Y., Balint Lahat N., Winkler T., Laue K., Ben-David U., Barshack I., Maoz B.N., and Satchi-Fainaro R. CCL2 blockade combined with PD-1/P-selectin immunomodulators impedes breast cancer brain metastasis. Brain, 2024, doi:10.1093/brain/awae347 (ONLINE AHEAD OF PRINT) . IF=10.6.

 

  1. Zerbib J. *, Ippolito M. R.*, Eliezer Y., Reuveni E., Viganò S., De Feudis G., Savir Kadmon A., Martin S., Leor G., Berstler J., Laue K., Cohen-Sharir Y., Scorzoni S., Vazquez F., Ben-David U. #, and Santaguida S.#. Human aneuploid cells depend on the RAF/MEK/ERK pathway for overcoming increased DNA damage. Nature Communications, 2024, 15(1):7772, doi:10.1038/s41467-024-52176-x. IF=14.7.  

 

  1. Ippolito M. R.*, Zerbib J. *, Reuveni E., De Feudis G., Eliezer Y., Savir Kadmon A., Martin S., Vigen S., Leor G., Berstler J., Laue K., Cohen-Sharir Y., Scorzoni S., Vazquez F., Santaguida S.#, and Ben-David U. #. Increased RNA and protein degradation is required for counteracting transcriptional burden and proteotoxic stress in human aneuploid cells. Cancer Discovery, 2024, 14(12):2532-2553, doi: 10.1158/2159-8290.CD-23-0309. IF=39.4.

 

# Highlighted in a Commentary in Cancer Disocvery (doi: 10.1158/2159-8290.CD-24-1350)

# A news article in Drug Discovery News (https://www.drugdiscoverynews.com/targeting-aneuploidy-to-treat-cancer-16262)

 

  1. Martin S., Vaites L.P., Mazzagatti A., Scorzoni S., Beznoussenko G.V., Gunn A.L., Eliezer Y., Leor G., Ben-Yishay T., Loffreda A., Bedin F., Di Bona M., Garrè M., Vasapolli P., Parazzoli D., Mironov A.A., Cuomo A., Bakhoum S.F., Ben-David U., Hatch E.M., Ly P., Harper J.W., and Santaguida S. A p62-dependent rheostat dictates micronuclei catastrophe and chromosome rearrangements. Science, 2024, 385(6712):eadj7446, doi:10.1126/science.adj7447. IF=47.7.

 

# Highlighted on the Cover of the journal

 

  1. Nair N.U. *, Schäffer A.A. *, Gertz E.M. *, Cheng K., Zerbib J., Sahu A.D., Leor G., Shulman E. D., Aldape, K.D., Ben David U., and Ruppin E. Chromosome 7 gain compensates for chromosome 10 loss in glioma. Cancer Research, 2024, 84(20):3464-3477, doi: 10.1158/0008-5472.CAN-24-1366 . IF=11.2.

 

  1. Stavish D., Price C.J., Gelezauskaite G., Leonhard K.A. Taapken S.M., McIntire E.M., Laing O., James B.M., Riley J.J., Zerbib J., Baker D., Harding A.L., Jestice L.H., Eleveld T.F., Gillis A.J.M., Hillenius S., Looijenga L.H.J., Gokhale P.J.G., Ben-David U., Ludwig T., and Barbaric I. Feeder-free culture of human pluripotent stem cells drive MDM4-mediated gain of chromosome 1q. Stem Cell Reports, 2024, 18:S2213-6711(24), doi: 10.1016/j.stemcr.2024.06.003. IF=5.9.

 

  1. Jubran J. *, Slutsky R. *, Rozenblum N., Rokach L., Ben-David U. #, and Yeger-Lotem E. #. Machine-learning analysis reveals an important role for negative selection in shaping cancer aneuploidy landscapes. Genome Biology, 2024, 25(1):95, doi: 10.1186/s13059-024-03225-7. IF=12.3.

 

  1. Lakshmi R.B., Nayak P., Raz L., Sarkar A., Saroha A., Kumari P., Nair V.M., Pauly D.K., Sajana S., Sanush, M.G., Agasti S.S., Paul R., Ben-David U., Manna T.K. CKAP5 regulates microtubule-chromosome attachment fidelity by stabilizing CENP-E at kinetochores. EMBO Reports, 2024, doi: 10.1038/s44319-024-00106-9. IF=8.8.

 

2023

  1. Sacconi A. *, Muti P. *, Pulito C., Pellini R., Strano S., Ben-David U., Bossi P. # and Blandino G. #. Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patients. Molecular Cancer, 2023, 22(1):192, doi: 10.1186/s12943-023-01905-9. IF=37.3.

 

  1. de la Vega A.A., Temiz N.A., Tasakis R., Somogyi K., Reuveni E., Ben-David U., Stenzinger A., Poth, T., Papavasiliou N., Harris R.S., and Sotillo R. Acute Expression of human APOBEC3CB in mice causes lethality associated with RNA editing. Genome Biology, 2023, 24(1):267, doi: 10.1186/s13059-023-03115-4. IF=18.0.

 

  1. Chang T., Cao Y., Shulman E.D., Ben-David U., Schäffer A.A., and Ruppin E. Optimizing cancer immunotherapy response prediction by tumor aneuploidy score and fraction of copy number alterations. Npj Precision Oncology, 2023, 7(1):54. doi: 10.1038/s41698-023-00408-6. IF=10.1

 

  1. Stossel C.,  Raitses-Gurevich M., Atias D., Beller T., Gorman-Glick Y., Halperin S., Peer E., Denroche R.E., Zhang A., Notta F., Wilson J.M., O’Kane G., Haimov Talmoud E., Amison N., Schvimer M., Salpether S., Bar V., Tirosh I., Tal R., Dinstag G., Eliezer Y., Ben-David U., Straussman R., Gavert N., Gallinger S., Berger R., Golan T. Spectrum of response to platinum and PARP inhibitors in germline BRCA-associated pancreatic cancer in the clinical and preclinical setting. Cancer Discovery, 2023, 13(8)1826-1843, doi: 10.1158/2159-8290.CD-22-0412. IF=39.4.

 

  1. Altea-Manzano P., Doglioni G., Liu Y., Cuadros A.M., Nolan E., Fernandez-Garcia J., Wu Q., Montagne A., Planque M., Laue K.J., Cidre-Aranaz F., Liu X., Marin-Bejar O., Van Elsen J., Vermeire I., Broekaert D., Demeyer S., Spotbeen X., Alkan H.F., Demicco M., Rabas N., Riera-Domingo C., Richard F., Geukens T., Maxim De Schepper14, Sophia Leduc5, Sigrid Hatse5, Yentl Lambrechts5, Emily Jane Kay15, Sergio Lilla15, Alekseenko A., Geldhof V., Boeckx B.,, de la Calle Arregui C., Floris G., Swinnen J., Marine J.C., Lambrechts D., Pelechano V., Mazzone M., Zanivan S., Cools J., Wildiers H., Baud V., Grünewald T.G.P., Ben-David U., Desmedt C., Malanchi I., Fendt S.-M. A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in preo-metastatic NF-κB signaling. Nature Cancer, 2023, 4(3):344-364, doi: 10.1038/s43018-023-00513-2. IF=23.2.

 

  1. Garribba L.*, De Feudis G.*, Martis V., Galli M., Dumont M., Eliezer Y., Wardenaar R., Ippolito M., Iyer D.R., Tijhuis A.E., Spierings D.C.J., Schubert M., Rind N., Foijer F., Ben-David U., Fachinetti D., Doksani Y., and Santaguida S. Short-term molecular consequences of chromosome mis-segregation for genome stability. Nature Communications, 2023, 14(1):1353, doi: 10.1038/s41467-023-37095-7. IF=17.7.

 

2022

  1. Waissengrin B., Zahavi T., Salmon‐Divon M., Goldberg A., Wolf I., Rubinek T. Winkler T., Farkash O., Grinshpun A., Zubkov A., Khatib M., Strulov Shachar S., Keren N., Carmi-Levy I., Ben-David U., and Amir Sonnenblick1,2*. The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer. ESMO Open, 2022, 7(6):100648, doi: 10.1016/j.esmoop.2022.100648. IF=5.3.

 

  1. Nahmad A.D.*, Reuveni E.*, Goldschmidt E.*, Tenne T., Liberman M., Horovitz-Fried M., Khosravi R., Kobo H., Reinstein E., Madi. A. #, Ben-David U. #, and Barzel A. # Frequent aneuploidy in primary human T cells following CRISPR-Cas9 cleavage. Nat Biotechnol, 2022, 40(12):1807-1813, doi: 10.1038/s41587-022-01377-0. IF=54.9.

# Highlighted in news stories in the popular press (Haaretz, Jerusalem Post, ScienceDaily, and more)

  1. Hoge A.C.H.*, Getz M.*, Beroukhim R., Golub T.R., Ha G.# and Ben-David U.# DNA-based copy number analysis confirms genomic evolution of PDX models. npj Precision Oncology, 2022, 6(1):30. IF=10.1

 

  1. Prasad K., Bloomfield M., Levi H., Keuper K., Bernhard S.V., Baudoin N.C., Leor G., Eliezer Y., Giam M., Wong C.K., Rancati G., Storchova Z., Cimini D., and Ben-David U. # Whole-genome duplication shapes the aneuploidy landscape of human cancers. Cancer Research, 2022, 3;82(9):1736-1752., doi:10.1158/0008-5472.CAN-21-2065. IF=12.7

2021

  1. Ippolito M., Martis V., Hong C., Wardenaar R., Zerbib J., Spierings D.C.J., Ben-David U., Foijer F., and Santaguida S. Gene copy-number changes and chromosomal instability induced by aneuploidy confer resistance to chemotherapy. Developmental Cell, 2021, S1534-5807(21)00562-1, doi: 10.1016/j.devcel.2021.07.006. IF=10.1

 

# Mentioned on the Cover of the journal

 

  1. Vaz S., Ferreira F.J., Macedo J.C., Leor G., Ben-David U., Bessa J., and Logarinho E. BMF repression by FoxM1 inhibits anoikis during mitosis and is a biomarker for antimitotic chemotherapy response. Cell Death & Disease, 2021, 12(6):542, doi: 10.1038/s41419-021-03822-5. IF=8.5.

 

  1. Wang R.W., Vigano S., Ben-David U., Amon A., and Santaguida S. Aneuploid senescent cells activate NF-κB to promote their immune clearance by NK cells. EMBO Reports 2021, 22(8):e52032, doi: 10.15252/embr.202052032. IF=8.8.

 

  1. Cohen-Sharir Y., McFarland J., Abdusamad M., Marquis C., Bernhard S.V., Kazachkova M., Tang H., Ippolito M.R., Laue K., Zerbib J., Malaby H.L.H., Jones H., Stautmeister L.-M., Bockaj I., Wardenaar R., Lyons N., Nagaraja A., Bass A.J., Spierings D.C.J., Foijer F., Beroukhim R., Santaguida S., Golub T.R., Stumpff  J., Storchova Z., and Ben-David U.# Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition. Nature 2021, 590(7846):486-491, doi: 10.1038/s41586-020-03114-6. IF=50.0

 

# "Research Highlight” in Cancer Discovery (doi: 0.1158/2159-8290.CD-RW2021-017)

# “News & Views” comment in Nature Communications (doi: 10.1038/s41467-021-23965-5)

# A provisional patent application was submitted based on this work.

# Highlighted in news stories in the popular press (New York Post, Ynet, GEN, Doctors Only, and more)

# “Best Publication Award” of the Faculty of Medicine at TAU for the year 2021
# Inspired clinical trials conducted in the U.S.A. by Amgen and Volastra

2020

 

  1. Replogle J., Zhou W., Amaro A., McFarland J., Villalobos-Oritz M., Ryan J., Letai, A., Yilmaz O., Sheltzer J., Lippard S., Ben-David U., and Amon A. Aneuploidy increases resistance to chemotherapeutics by antagonizing cell division. Proc Natl Acad Sci U S A, 2020, 117(48):30566-30576, doi.org/10.1073/pnas.2009506117. IF=11.2.
  2. Winkler T. and Ben-David U. # Elevated ACE2 expression levels in tumor-adjacent tissues of cancer patients. International Journal of Cancer, 2020, 147(11):3264-3266, doi.org/10.1002/ijc.33145. IF=7.4

# Selected for a special issue for the 2021 World Cancer Day

  1. Enache O.M.*, Rendo V.*, Abdusamad M., Lam D., Davison D., Pal S., Currimjee N., Hess J., Sanson K., Pantel S., Nag A., Thorner A., Root D., Doench J.G., Vazquez F., Beroukhim R., Golub T.R., and Ben-David U.# Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nature Genetics, 2020, 52(7):662-668, doi: 10.1038/s41588-020-0623-4. IF=38.3

# The cover of the journal was dedicated to this article

# “Research Highlight” in Cancer Discovery (doi: 10.1158/2159-8290.CD-RW2020-081)

# Invited paper presentation in JRNLclub (https://jrnlclub.org/)

# A provisional patent application was submitted based on this work

 

  1. Corsello S.M., Nagari R.T., Spangler R.D., Rossen J., Kocak M., Bryan J.G., Humeidi R., Peck D., Wu X., Tang A.A., Wang V.M., Bender S.A., Lemire E., Narayan R., Montgomery P., Ben-David U., Chen Y., Rees M.G., Lyons N.J., McFarland J.M., Wong B.T., Wang L., Dumont N., O'Hearn P.J., Stefan E., Doench J.G., Greulich H., Meyerson M., Vazquez F., Subramanian A., Roth J.A., Bittker J.A., Boehm J.S., Mader C.C., Tsherniak A., and Golub T.R. Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. Nature Cancer, 2020, 1(2):235-248, doi: 10.1038/s43018-019-0018-6. IF=23.2

2018

 

  1. Ben-David U., Siranosian B., Ha G., Tang H., Oren Y., Hinohara K., Strathdee c.A., Dempster J., Lyons N.J., Burns R., Nag A., Kugener G., Cimini B., Tsvetkov P., Maruvka Y.E., O’Rourke R., Garrity A., Tubelli A.A., Bandopadhayay P., Tsherniak A., Vazquez F., Wong B., Birger C., Ghandi M, Thorner A.R., Bittker J.A., Meyerson M., Getz G., Beroukhim R. and Golub T.R. Genetic and transcriptional evolution alters cancer cell line drug response. Nature, 2018, 560(7718):325-330, doi: 10.1038/s41586-018-0409-3. IF=50.0

# The cover of the journal was dedicated to this article

# Highlighted in a Broad Press Release and Video

# Highlighted in a “News and Views” article in Disease Models & Mechanisms
(doi: 10.1242/dmm.037366)

# Highlighted in news stories in the popular press (STAT+, Haaretz, and more)

  1. Abdeen S.A., Ben-David U., Maly B. and Aqueilan R. Somatic loss of WWOX drives triple-negative breast cancer through perturbation of TP53. Cell Death & Disease, 2018, 9(8):832, doi: 10.1038/s41419-018-0896-z. IF =8.5

2017

  1. Ben-David U., Ha G., Tseng Y.Y., Greenwald N.F., Oh C., Shih J., McFarland J.M., Wong B., Boehm J.S., Beroukhim R. and Golub T.R. Patient-derived xenografts undergo mouse-specific tumor evolution. Nature Genetics, 2017, 49(11):1567-1575, doi:10.1038/ng.3967. IF= 38.3

# Highlighted in a “News and Views” article in Nature Genetics (doi:10.1038/ng.3983)

# Highlighted in two news stories in Nature (doi:10.1038/nature.2017.22782 and
doi: 10.1038/d41586-018-05890-8)

# Highlighted in a news story in Cancer Discovery (doi: 10.1158/2159-8290.CD-NB2017-151)

# Highlighted in news stories in the popular press (The Scientist, Ars Technica, and more)

# “The Research Parasite Award” for outstanding secondary data analysis

 

2016

 

  1. Bi W.L., Horowtiz P., Greenwald N., Abedalthagafi M., Agarwalla P.K., Gibson W.J., Mei Y, Schumacher S.E., Ben-David U., Chevalier A., Carter S.L., Tiao G., Brastianos P.K., Ligon A.H., Ducar M., MacConaill L.E., Laws E.R., Santagata S., Beroukhim R., Dunn IF. Landscape of genomic alterations in pituitary adenomas. Clinical Cancer Research, 2016, 23(7):1841-1851, doi: 10.1158/1078-0432.CCR-16-0790. IF=12.5

 

  1. Aguirre A., Meyers R., Weir B., Vazquez F., Zhang C.Z., Ben-David U., Cook A., Ha G., Harrington W., Doshi M., Gill S., Xu H., Ali L., Jiang G., Pantel S., Lee Y., Goodale A., Cherniack A., Oh C., Kryukov G., Cowley G., Garraway L., Stegmaier K., Roberts C., Golub T.R., Meyerson M., Root D., Tsherniak A., and Hahn W. Genomic copy number dictates a gene-independent cell response to CRISPR-Cas9 targeting. Cancer Discovery, 2016, 6(8):914-29, doi: 10.1158/2159-8290.CD-16-0154. IF=39.4

 

  1. Ben-David U., Ha G., Khadka P., Jin X., Wong B., Franke L. and Golub T.R. The landscape of chromosomal aberrations in breast cancer mouse models reveals driver-specific routes to tumorigenesis. Nature Communications, 2016, 7:12160, doi:10.1038/ncomms12160. IF=14.9

 

  1. Lamm N., Ben-David U., Kerem B. and Benvenisty N. Genomic instability in human pluripotent stem cells arises from replicative stress and chromosome condensation defects. Cell Stem Cell, 2016, 18(2): 253-61, doi: 10.1016/j.stem.2015.11.003. IF=24.6

 

2015

 

  1. Ben-David U., Cowell Ian G., Austin Caroline C. and Benvenisty N. Controlling the survival of human pluripotent stem cells by small molecule-based targeting of topoisomerase II alpha. Stem Cells, 2015, 33(3): 1013-9, doi: 10.1002/stem.1888. IF=6.3

 

# Highlighted in the journal's website

 

2014

 

  1. Weissbein U., Ben-David U. and Benvenisty N. Virtual karyotyping reveals greater chromosomal stability in neural cells derived by transdifferentiation than those from stem cells. Cell Stem Cell, 2014, 15(6):687-91, doi: 10.1016/j.stem.2014.10.018. IF=24.6

 

  1. Ben-David U., Arad G., Weissbein U., Mandefro B., Maimon A., Narwani K., Clark A.T., Andrews P.W., Benvenisty N., and Biancotti J.C. Aneuploidy induces profound changes in gene expression, proliferation and tumorigenicity of human pluripotent stem cells. Nature Communications, 2014, 5:4825, doi: 10.1038/ncomms5825. IF=14.9

 

  1. Ben-David U.*, Biran A.*, Scaffidi P., Boehringer M., Meshorer E. and Benvenisty N. Elimination of undifferentiated cancer cells by pluripotent stem cell inhibitors. Journal of Molecular Cell Biology, 2014, 6(3):267-9, doi: 10.1093/jmcb/mju012. IF=6.2

 

  1. Ben-David U. and Benvenisty N. Chemical ablation of tumor-initiating human pluripotent stem cells. Nature Protocols, 2014, 9(3):729-40, doi: 10.1038/nprot.2014.050. IF=13.5

 

2013

 

  1. Ben-David U., Nudel N. and Benvenisty N. Immunologic and chemical targeting of the tight-junction protein Claudin-6 eliminates tumorigenic human pluripotent stem cells. Nature Communications, 2013, 4:1992, doi:10.1038/ncomms2992. IF=14.9

 

# Highlighted in the journal's website and press release

# Highlighted in "Scientific American", "A Week in Science" and "Lab Times" magazines

# "Article of the month” award, Life Sciences Institute, Hebrew University

 

  1. Ben-David U., Gan Q.F., Golan-Lev T., Arora P., Yanuka O., Oren Y.S., Leikin-Frenkel A., Graf M., Garippa R., Boehringer M., Gromo G. and Benvenisty N. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell, 2013, 12(2):167-79, doi: 10.1016/j.stem.2012.11.015. IF=24.6

 

# "Research Highlight" in Nature Chemical Biology, 2013, 9(3): 139

            # "Research Highlight" in Nature/SciBX, 2013, 6(5): doi:10.1038/scibx.2013.126

            # “Article of the month” award, Life Sciences Institute, Hebrew University

# US granted patent 9,456,998, of May 22, 2013, SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS

  1. Lee P., Martin N.T., Nakamura K., Azghadi S., Amiri M., Ben-David U., Perlman S., Gatti R.A., Hu H. and Lowry W.E. SMRT compounds abrogate cellular phenotypes of Ataxia Telangiectasia in neural derivatives of patient specific hiPSCs. Nature Communications, 2013, 4:1824, doi:10.1038/ncomms2824. IF=14.9

 

  1. Ben-David U., Mayshar Y. and Benvenisty N. Virtual karyotyping of pluripotent stem cells on the basis of their global gene expression profiles. Nature Protocols, 2013, 8(5): 989-97,  doi: 10.1038/nprot.2013.051. IF=13.5

 

# Highlighted in the journal's website

 

2012

 

  1. Ben-David U. and Benvenisty N. High prevalence of evolutionarily conserved and species-specific genomic aberrations in mouse pluripotent stem cells. Stem Cells, 2012, 30(4):612-22, doi: 10.1002/stem.1057. IF=6.3

 

            # Highlighted on the cover of the journal and in its website

            # “Article of the month” award, Life Sciences Institute, Hebrew University

 

2011

 

  1. Ben-David U., Mayshar Y. and Benvenisty N. Large-scale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells. Cell Stem Cell, 2011, 9(2):97-102, doi: 10.1016/j.stem.2011.06.013. IF=24.6

 

            # Highlighted in the Editorial and in a Perspective article published in the same issue

            # “Article of the month” award, Life Sciences Institute, Hebrew University

 

2010

 

  1. Mayshar Y.*, Ben-David U.*, Lavon N., Biancotti J.C., Yakir B., Clark A.T., Plath K., Lowry W.E. and Benvenisty N. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell, 2010, 7(4):521-31, doi: 10.1016/j.stem.2010.07.017. IF=24.6

 

            # "Research Highlight" in Nature Reviews Cancer, 2010, 10(11):742

            # “Research Highlight” in Nature Methods, 2010, 7(12): 948-9

            # “Article of the year” award, 2010, Life Sciences Institute, Hebrew University

 

 

SUBMITTED MANUSCRIPTS
 

  1. Nagaraja K.N., Wu, Z., Zhou, J., Goss L.B., Jeffries A., Bao C., Liu Y., Ho Z.V., Wang V.M., McFarland J.M., Ben-David U., Augustin J., Liao J., Zhang Y., Zhang C.-Z., Rustgi A.K., Wong K.-K., and Bass, A.J.  Cyclin E1 Amplification Promotes Chromosomal Instability and Distinct Vulnerabilities in Gastroesophageal Adenocarcinoma. Submitted.

 

  1. Rabinowitz R. *, Shor O. *, Zerbib J. *, Herman S., Zelikson N., Mediwale S., Yom-Tov N., Ben-David U., Benninger F.  # and Offen D #. Computationally engineered CRISPR-SpyCas9 high-fidelity variants with improved specificity and reduced non-specific DNA damage. Submitted. https://doi.org/10.1101/2023.04.11.536265 (bioRxiv)

 

  1. Sinha S., Sinha N., Garcia M.P., Tarrab A.V., Nyugen T., Liu L., Patiyal S., Mukherjee S., Madan S., Flanigan G., Meerzaman D., Ben-David U., Deshpande A.J., and Ruppin E. DeepTarget Predicts Primary and Secondary Targets of Cancer Drugs by integrating large-scale genetic and drug screens. Submitted.

 

  1. Rozenblum N., Ben-Yishay T., Wainer-Katsir L, and Ben-David U. # Cancer cells exhibit a distinct, complementary, aneuploidy-dependent response to Tumor Treating Fields and Spindle Assembly Checkpoint inhibition. Submitted.

 

  1. Viganò S., Scorzoni S., Pontano-Vaites L., Barrio L., Loffreda A., Donzel D., Eliezer Y., Marenda M., Ben-David U., Viero G., Milàn M., Harper W., and Santaguida S. Aneuploid cells undergo autophagy-mediated ribosome degradation following proteostasis disruption. Submitted.

 

  1. Bloomfield M., Huth S., McCausland D., Saad R., Bano N., Chau T., Sweet M., Baudoin N., McCaffrey A., Fluet K., Schmelz E.M., Ben-David U., and Cimini D. Cell and nuclear size are associated with chromosomal instability and tumorigenicity in cancer cells that undergo whole genome doubling. Submitted. https://doi.org/10.1101/2025.03.28.645986  (bioRxiv).

 

  1. Mahdi M.S., Nechytailo N., Salmonowicz H., Zheng R., Jasterzebska A., Winkler T., Cocom-Chan B., Mudarth D., Marusiak A.A., Serwa R., Ben-David U., and Szczepanowska K. Dysregulation of mitochondrial proteases alters the components of multimeric protein complexes in human cancers. Submitted.

 

  1. Saad R., Shamir R. #, and Ben-David U. # Integrating gene expression, mutation and copy number data to identify driver genes of recurrent chromosome-arm losses. Submitted.

https://doi.org/10.1101/2025.02.22.639659 (bioRxiv).

 

  1. Anand U., Bloomberg A., Badarudeen B., Mukhopadhyay S., Bhattacharjee P., Ramakrishnan S., Ben-David U. and Manna. T.K. FBXW7 controls centriole amplification via Plk4-dependent degradation of STIL. Submitted.

 

REVIEWS & PERSPECTIVES

 

2025

  1. Zerbib J., Bloomberg A. and Ben-David U. # Targeting vulnerabilities of aneuploid cells for cancer therapy. Trends Cancer 2025, https://doi.org/10.1016/j.trecan.2025.04.005. IF=14.3.

2024

  1. Sdeor E., Okada H., Saad R., Ben-Yishay T. and Ben-David U. # Aneuploidy as a driver of human cancer. Nature Genetics 2024, 56(10):2014-2026, doi: 10.1038/s41588-024-01916-2. IF=31.7.

2023

  1. Prasad K. and Ben-David U. # A balance act: how whole-genome doubling and aneuploidy interact in human cancer. Oncotarget, 2023, 26(14):382-383, doi:10/18632/oncotarget.28374. IF=3.3

2022

  1. Eliezer Y. and Ben-David U.# Genome doubling causes double trouble. Nature, 2022, doi.org/10.1038/d41586-022-00849-2w. IF=50.0

2021

 

  1. Cohen-Sharir Y. and Ben-David U.# Relevance of aneuploidy for cancer therapies targeting the spindle assembly checkpoint and KIF18A. Molecular & Cellular Oncology, 2021, 8(3):1915075, doi.org/10.1080/23723556.2021.1915075. IF=1.2

 

2020

 

  1. Rendo V., Enache O. and Ben-David U. # Adding to the CASeload: Unwarranted Cas9-induced activation of the p53 pathway. Molecular & Cellular Oncology, 2020, 7(5):1789419, doi.org/10.1080/23723556.2020.1789419. IF=1.2
  2. Ben-David U.# and Amon A. Context is everything: aneuploidy in cancer. Nature Reviews Genetics, 2020, 21(1):44-62, doi: 10.1038/s441576-019-0171-x. IF=53.2

# Highlighted on the cover of the journal

 

2019

  1. Ben-David U. #, Beroukhim R. and Golub T.R. Genomic evolution of cancer models: perils and opportunities. Nature Reviews Cancer, 2019, 19(2):97-109, doi: 10.1038/s41568-018-0095-3. IF=60.7.

2018

  1. Odorico. J., Adams A., Melton D., Greenstein G., Hwa A., Nostro C., Rezania A., Oberholzer J., Pipeleers D., Yang L., Cowan C., Huangfu D., Egli D., Ben-David U., Vallier L., Grey S., Tang Q., Roep B., Ricordi C., Naji A., Orlando G., Anderson D., Poznansky M., Ludwig B., Tomei A., Greiner D., Graham M., Carpenter M., Migliaccio G., D’Amour K., Hering B., Piemonti L., Berney T., Rickels M., Kay T. and Markmann J. Report of the Key Opinion Leaders Meeting on Stem Cell-Derived Beta Cells. Transplantation, 2018, 102(8):1223-1229, doi: 10.1097/TP.0000000000002217. IF=4.9

2017

  1. Andrews P.W., Ben-David U., Benvenisty N., Coffey P., Eggan K., Knowles B.B., Nagy A., Pera M., Reubinoff B., Rugg-Gunn P.J., Stacey G.N. Assessing the safety of human pluripotent stem cells (PSCs) and their derivatives for clinical applications. Stem Cell Reports, 2017, 9(1):1-4, doi: 10.1016/j.stemcr.2017.05.029. IF=7.8

 

2015

 

  1. Heslop A.J., Hammond T.G., Santeramo I., Piella A.T., Hopp I., Zhou J., Baty R., Graziano, E.I., Bernabe P., Shaw D.A., Bunn I., Caron A., Skold P., Andrews P.W., Baxter M., Hay D., Hamdam J., Sethu S., Sharpe M.E., Patel S., Jones D.R., Reinhardt J., Danen E.H.J., Ben-David U., Stacey G., Bjorquist P., Rowe, C., Pellegrini G., Antoine D., Cross M.J., Murray P., Williams D., Kitteringham N.R., Park B.K. and Goldring C.E.P. Understanding the risks of stem cell-based therapeutics. Stem Cells Translational Medicine, 2015, 4(4):389-400, doi: 10.5966/sctm.2014-0110. IF=6.9

 

2014

 

  1. Ben-David U.# Genomic instability, driver genes and cell selection: Projections from cancer to stem cells. Biochim Biophys Acta, 2014, 1849(4):427-35, doi: 10.1016/j.bbagrm.2014.08.005. IF=4.5

 

# Highlighted on the cover of the journal

 

  1. Weissbein U., Benvenisty N. and Ben-David U.# Genome maintenance in pluripotent stem cells. Journal of Cell Biology 2014, 204(2):153-63, doi: 10.1083/jcb.201310135. IF=10.5

 

2013

 

  1. Ben-David U.# Flowing through the CRISPR-CAScade: Will genome editing boost cell therapies? Molecular and Cellular Therapies, 2013, 1:3, doi:10.1186/2052-8426-1-3. No IF available.

 

  1. Ben-David U., Nissenbaum J. and Benvenisty N. New balance in pluripotency: reprogramming with lineage specifiers. Cell, 2013, 153(5): 939-40, doi: 10.1016/j.cell.2013.04.051. IF=41.6

 

2012

 

  1. Ben-David U., Kopper O. and Benvenisty N. Expanding the boundaries of embryonic stem cells. Cell Stem Cell, 2012, 10(6):666-77, doi: 10.1016/j.stem.2012.05.003. IF=24.6

 

  1. Ben-David U. and Benvenisty N. Analyzing the genomic integrity of stem cells. StemBook, 2012, doi: 10.3824/stembook.1.50.1, http://www.stembook.org. No IF available.

 

  1. Ben-David U., Mayshar Y. and Benvenisty N. Significant acquisition of chromosomal aberrations in human adult mesenchymal stem cells: Response to Sensenbé et al. Cell Stem Cell, 2012, 10(1):10-11, doi: 10.1016/j.stem.2011.12.007. IF=24.6

 

2011

 

  1. Goldring C.E.P., Duffy P.A., Benvenisty N., Andrews P.W., Ben-David U., Eakins R., French N., Hanley N.A., Kelly L., Kitteringham N.R., Kurth J., Ladenheim D., Laverty H., McBlane J., Narayanan G., Patel S., Reinhardt J, Rossi A., Sharpe M. and Park K. Assessing the safety of stem cell therapeutics. Cell Stem Cell, 2011, 8(6):618-28, doi: 10.1016/j.stem.2011.05.012. IF=24.6

 

# The cover and the editorial of the journal were dedicated to this article

 

  1. Ben-David U. and Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nature Reviews Cancer, 2011, 11(4): 268-77, doi: 10.1038/nrc3034. IF=60.7

 

            # The cover and the editorial of the journal were dedicated to this article

 

2010

 

  1. Ben-David U., Benvenisty N. and Mayshar Y. Genetic instability in human induced pluripotent stem cells: Classification of causes and possible safeguards. Cell Cycle, 2010, 9(23): 4603-4, doi: 10.4161/cc.9.23.14094. IF=4.5

 

 

Grants

2025-2026        Northwestern-Tel Aviv-Toronto Joint Call for Proposals: Longevity and Healthy Aging

2024-2028       The United States – Israel Binational Science Foundation (BSF) Research Grant (co-PI with Dr. Jason Sheltzer from Stanford)

2023-2026       The Israel Cancer Research Fund (ICRF) Project Grant

2021-2026       The European Research Council (ERC) Starting Grant

2021-2026       Israel Science Foundation Project Grant

2021-2025       Israel Precision Medicine Partnership (IPMP) Research Grant (co-PI with Prof. Ittai Ben-Porath and Dr. Amir Sonnenblick)

אוניברסיטת תל אביב עושה כל מאמץ לכבד זכויות יוצרים. אם בבעלותך זכויות יוצרים בתכנים שנמצאים פה ו/או השימוש שנעשה בתכנים אלה לדעתך מפר זכויות
שנעשה בתכנים אלה לדעתך מפר זכויות נא לפנות בהקדם לכתובת שכאן >>
אוניברסיטת תל-אביב, רחוב חיים לבנון 30, 6997801.